472 related articles for article (PubMed ID: 26595527)
1. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
2. Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition.
Ditano JP; Sakurikar N; Eastman A
Cell Cycle; 2021 Jul; 20(13):1308-1319. PubMed ID: 34156324
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells.
Tu YS; Kang XL; Zhou JG; Lv XF; Tang YB; Guan YY
Eur J Pharmacol; 2011 Nov; 670(2-3):356-64. PubMed ID: 21958871
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
Warren NJH; Eastman A
J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
6. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Sampath D; Shi Z; Plunkett W
Mol Pharmacol; 2002 Sep; 62(3):680-8. PubMed ID: 12181445
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
9. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
11. Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
Hsieh WT; Lin HY; Chen JH; Lin WC; Kuo YH; Wood WG; Lu HF; Chung JG
Environ Toxicol; 2015 Sep; 30(10):1205-15. PubMed ID: 24706497
[TBL] [Abstract][Full Text] [Related]
12. Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage.
Bačević K; Lossaint G; Achour TN; Georget V; Fisher D; Dulić V
Sci Rep; 2017 Oct; 7(1):13429. PubMed ID: 29044141
[TBL] [Abstract][Full Text] [Related]
13. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
15. DNA damage-induced degradation of Cdc25A does not lead to inhibition of Cdk2 activity in mouse embryonic stem cells.
Koledova Z; Kafkova LR; Krämer A; Divoky V
Stem Cells; 2010 Mar; 28(3):450-61. PubMed ID: 20104581
[TBL] [Abstract][Full Text] [Related]
16. DNA repair factor RAD18 and DNA polymerase Polκ confer tolerance of oncogenic DNA replication stress.
Yang Y; Gao Y; Mutter-Rottmayer L; Zlatanou A; Durando M; Ding W; Wyatt D; Ramsden D; Tanoue Y; Tateishi S; Vaziri C
J Cell Biol; 2017 Oct; 216(10):3097-3115. PubMed ID: 28835467
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
18. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
19. Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.
Oakes V; Wang W; Harrington B; Lee WJ; Beamish H; Chia KM; Pinder A; Goto H; Inagaki M; Pavey S; Gabrielli B
Cell Cycle; 2014; 13(20):3302-11. PubMed ID: 25485510
[TBL] [Abstract][Full Text] [Related]
20. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Montano R; Chung I; Garner KM; Parry D; Eastman A
Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
